Search clinical trials for: INC424 / Ruxolitinib

Total 353 results

Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Novartis Pharmaceuticals

Active, not recruiting

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

Graft vs Host Disease

Japan, Slovakia, Taiwan, Spain, Korea, Republic of, Thailand, Canada, Russian Federation, Italy, Turkey, India, Czechia, Brazil, Switzerland
Novartis Pharmaceuticals

Completed

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

Myelofibrosis

Belgium, Colombia, Canada, Italy, Spain, Austria, Germany, Czechia, Thailand, Hungary, Greece, Argentina, Brazil, Israel, Russian Federation, Mexico, Portugal, South Africa, Tunisia, Slovakia, Saudi Arabia, Poland, Algeria, Ireland, Mor...
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.

Thalassemia Major

Thailand, Turkey, Italy, Lebanon, Greece
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/Very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
Marcelo Iastrebner
Novartis

Unknown

Ruxolitinib in the Treatment of Covid-19

COVID-19
Novartis Pharmaceuticals
Incyte Corporation

Completed

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

Cytokine Storm (Covid-19)

United States, Colombia, Turkey, Spain, United Kingdom, Germany, Peru, Russian Federation, Brazil, France, Mexico, Argentina
M.D. Anderson Cancer Center
Incyte Corporation

Terminated

Phase l/II Study of Ruxolitinib for Acute Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Novartis Pharmaceuticals

Completed

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Primary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MF

Taiwan, Japan, Korea, Republic of, China
M.D. Anderson Cancer Center
Helsinn Healthcare SA

Completed

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Myeloproliferative Diseases

United States
Novartis Pharmaceuticals

Completed

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Acute Graft Versus Host Disease

Belgium, Japan, Spain, France, Korea, Republic of, Canada, Italy, Denmark
John Mascarenhas
National Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...

Terminated

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Canada, United Kingdom
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Incyte Corporation

Completed

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Novartis Pharmaceuticals

Completed

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (MACS2030)

Primary Myelofibrosis (PMF) | Post Polycythaemia Myelofibrosis (PPV MF) | Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

United Kingdom
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
Novartis Pharmaceuticals

Completed

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)

Polycythemia Vera

Hungary, Italy, Belgium, Germany, Spain, Korea, Republic of, Israel, Canada, Turkey, France, Australia, India
Peter Hosein, MD
Novartis Pharmaceuticals; Incyte Corporation; University of Miami Sylvester Comprehensive...

Recruiting

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
Novartis Pharmaceuticals

Recruiting

CINC424A2X01B Rollover Protocol

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Thalassemia | Graft Versus Host Disease

Korea, Republic of, Belgium, Italy, Japan, Germany, Australia, Bulgaria, Chile, China, Denmark, Greece, Hungary, Israel, Lebanon, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Thailand, India, Mexico, Turkey, Fran...
John Mascarenhas

Completed

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (PRIME)

Myelofibrosis

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)

Corticosteroid Refractory Acute Graft vs Host Disease

Germany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

Hematologic Malignancy | Bronchiolitis Obliterans Syndrome

China
Julie Nangia
Incyte Corporation; Translational Breast Cancer Research Consortium

Recruiting

Ruxolitinib for Premalignant Breast Disease (TBCRC042)

Ductal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In Situ

United States
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Healthy Participants

United States
Beijing Friendship Hospital

Unknown

Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

Hemophagocytic Lymphohistiocytosis

China
Children's Hospital Medical Center, Cincinnati

Recruiting

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant (HSCT)

Bronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)

United States
University of Jena

Completed

Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam)

Covid-19

Germany
University of Michigan Rogel Cancer Center

Completed

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Hemophagocytic Syndrome (HPS)

United States
Margherita Maffioli

Unknown

Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy

Myelofibrosis

Italy
University of Pittsburgh

Withdrawn

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Severe Aplastic Anemia | Single Lineage Cytopenias, T-LGL | Hypoplastic MDS

United States
Qilu Hospital of Shandong University

Recruiting

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Myelofibrosis

China
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute; Thomas Jefferson University; Cornell University

Recruiting

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Lymphoma

United States
Children's Hospital Medical Center, Cincinnati

Completed

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

Solid Organ Transplant | Acute-graft-versus-host Disease | Chronic Graft-versus-host-disease

United States
University of Rochester
Incyte Corporation

Active, not recruiting

Topical Ruxolitinib in Chronic Hand Dermatitis

Chronic Hand Dermatitis

United States
Aaron R. Mangold

Completed

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

Necrobiosis Lipoidica

United States
Novartis Pharmaceuticals

Terminated

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Primary Myelofibrosis

Spain, Germany, Italy
Sichuan University

Not yet recruiting

MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

GVHD | Acute Stem Cell Transplant Complications

China
Multinational Center for Quality of Life Research...

Not yet recruiting

Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice (QoL-PV-R)

Polycythemia Vera
University of Rochester
Incyte Corporation

Completed

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

United States
Tianjin Medical University General Hospital

Withdrawn

Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorder Relapse

China
Qilu Hospital of Shandong University

Completed

Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis

Myelofibrosis
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Kantonsspital Aarau
Novartis; University Hospital, Basel, Switzerland; Clinical Trial Unit, University...

Terminated

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Cancer Cachexia

Switzerland
Stefanie Sarantopoulos, MD, PhD.
National Institutes of Health (NIH); Incyte Corporation; Rigel Pharmaceuticals

Not yet recruiting

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Chronic Graft Versus Host Disease

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States

Search clinical trials for: INC424 / Ruxolitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations